Genmab A/S Bispecific Antibodies Against CD3 and CD20 Patent
Summary
The European Patent Office published a patent application (EP4678661A3) for Genmab A/S concerning bispecific antibodies targeting CD3 and CD20. The patent abstract details their use in treating diseases requiring T cell-mediated killing of CD20-expressing cells.
What changed
The European Patent Office has published a patent application, EP4678661A3, filed by Genmab A/S. The application details bispecific antibodies that target both CD3 and CD20, and their potential use in treating diseases where T cell-mediated killing of CD20-expressing cells is desired. This publication represents the granting of a patent for this specific antibody technology.
While this is a patent publication and not a regulatory rule, it signifies intellectual property protection for Genmab A/S in the field of oncology therapeutics. Companies operating in this space, particularly those developing similar bispecific antibody therapies, should be aware of this granted patent. No immediate compliance actions are required for entities outside of Genmab A/S, but it may impact future research, development, and commercialization strategies in the oncology market.
Source document (simplified)
BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
Search Report EP4678661A3 Kind: A3 Mar 18, 2026
Applicants
Genmab A/S
Inventors
ENGELBERTS, Patrick, BREIJ, Esther, C. W., RADEMAKER, Rik, ALTINTAS, Isil, SATIJN, David, VERPLOEGEN, Sandra, RADERSMA, Riemke Van Dijkhuizen, VAN DEN BRINK, Edward, N., SCHUURMAN, Janine, PARREN, Paul
Abstract
Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
IPC Classifications
A61K 39/00 20060101AFI20260210BHEP A61P 35/00 20060101ALI20260210BHEP C07K 16/28 20060101ALI20260210BHEP C07K 16/30 20060101ALI20260210BHEP C07K 16/46 20060101ALI20260210BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.